Table 1.

p16 and COX-2 expression coupled with proliferation increases the risk of developing subsequent disease among women with DCIS.

Marker	n	Control	Case	HR (95% CI)
p16	70
High		24% (9/38)	28% (9/32)	0.17 (0.02,1.4)
Low		76% (29/38)	72% (23/32)
COX-2	70
High		58% (22/38)	53% (17/32)	0.79 (0.4, 1.7)
Low		42% (16/38)	47% (15/32)
Ki67	70
High		24% (9/38)	53% (17/34)	2.7 (1.2, 5.9)
Low		76% (29/38)	47% (15/32)
p16 High	18
Ki67 High		0 % (0/9)	89% (8/9)	15.1 (1.4, 161.4)
K67 Low		100% (9/9)	11% (1/9)
p16 Low	52
Ki67 High		31% (9/29)	39% (9/23)	1.1 (0.4, 3.4)
Ki67 Low		69% (20/29)	61% (14/23)
COX-2 High	39
Ki67 High		23% (5/22)	76% (13/17)	4.8 (0.8, 27.5)
K67 Low		77% (17/22)	24% (4/17)
COX-2 Low	31
Ki67 High		25% (4/16)	27% (4/15)	0.86 (0.2, 3.3)
Ki67 Low		75% (12/16)	73% (11/15)
Marker	n	Control	Case	HR (95% CI)
p16	70
High		24% (9/38)	28% (9/32)	0.17 (0.02,1.4)
Low		76% (29/38)	72% (23/32)
COX-2	70
High		58% (22/38)	53% (17/32)	0.79 (0.4, 1.7)
Low		42% (16/38)	47% (15/32)
Ki67	70
High		24% (9/38)	53% (17/34)	2.7 (1.2, 5.9)
Low		76% (29/38)	47% (15/32)
p16 High	18
Ki67 High		0 % (0/9)	89% (8/9)	15.1 (1.4, 161.4)
K67 Low		100% (9/9)	11% (1/9)
p16 Low	52
Ki67 High		31% (9/29)	39% (9/23)	1.1 (0.4, 3.4)
Ki67 Low		69% (20/29)	61% (14/23)
COX-2 High	39
Ki67 High		23% (5/22)	76% (13/17)	4.8 (0.8, 27.5)
K67 Low		77% (17/22)	24% (4/17)
COX-2 Low	31
Ki67 High		25% (4/16)	27% (4/15)	0.86 (0.2, 3.3)
Ki67 Low		75% (12/16)	73% (11/15)